64 related articles for article (PubMed ID: 8175105)
1. [Biological properties of hemagglutinin of herpes simplex virus type 1].
Yoshida T
Fukuoka Igaku Zasshi; 1994 Mar; 85(3):91-100. PubMed ID: 8175105
[TBL] [Abstract][Full Text] [Related]
2. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism.
Gerber SI; Belval BJ; Herold BC
Virology; 1995 Dec; 214(1):29-39. PubMed ID: 8525631
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b.
Rux AH; Lou H; Lambris JD; Friedman HM; Eisenberg RJ; Cohen GH
Virology; 2002 Mar; 294(2):324-32. PubMed ID: 12009874
[TBL] [Abstract][Full Text] [Related]
4. Glycosaminoglycans are not indispensable for the anti-herpes simplex virus type 2 activity of lactoferrin.
Marchetti M; Ammendolia MG; Superti F
Biochimie; 2009 Jan; 91(1):155-9. PubMed ID: 18534197
[TBL] [Abstract][Full Text] [Related]
5. Herpes simplex virus type 1-induced hemagglutination: glycoprotein C mediates virus binding to erythrocyte surface heparan sulfate.
Trybala E; Svennerholm B; Bergström T; Olofsson S; Jeansson S; Goodman JL
J Virol; 1993 Mar; 67(3):1278-85. PubMed ID: 8382294
[TBL] [Abstract][Full Text] [Related]
6. Effect of heparin on hemagglutinin of herpes simplex virus type 1.
Noda M; Inaba Y; Seno M; Kanamoto Y; Tokumoto S
Microbiol Immunol; 1993; 37(12):979-81. PubMed ID: 8133804
[TBL] [Abstract][Full Text] [Related]
7. Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice.
Cui FD; Asada H; Kishida T; Itokawa Y; Nakaya T; Ueda Y; Yamagishi H; Gojo S; Kita M; Imanishi J; Mazda O
Gene Ther; 2003 Dec; 10(25):2059-66. PubMed ID: 14595378
[TBL] [Abstract][Full Text] [Related]
8. Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide.
Argnani R; Boccafogli L; Marconi PC; Manservigi R
Gene Ther; 2004 Jul; 11(13):1087-98. PubMed ID: 15057264
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional features of the polycationic peptide required for inhibition of herpes simplex virus invasion of cells.
Trybala E; Olofsson S; Mårdberg K; Svennerholm B; Umemoto K; Glorioso JC; Bergström T
Antiviral Res; 2004 Jun; 62(3):125-34. PubMed ID: 15130536
[TBL] [Abstract][Full Text] [Related]
10. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection.
Wald A; Ashley-Morrow R
Clin Infect Dis; 2002 Oct; 35(Suppl 2):S173-82. PubMed ID: 12353203
[TBL] [Abstract][Full Text] [Related]
11. Influence of glycoproteins B, C and D on the conversion of virus-to-cell attachment from heparin sensitivity to resistance.
Seck T; Koch O; Lingen M; Falke D
Acta Virol; 1996 Sep; 40(4):179-85. PubMed ID: 9014007
[TBL] [Abstract][Full Text] [Related]
12. Characterization of herpes simplex virus type 1 recombinants that express and incorporate high levels of HCV E2-gC chimeric proteins.
Kouvatsis V; Argnani R; Tsitoura E; Arsenakis M; Georgopoulou U; Mavromara P; Manservigi R
Virus Res; 2007 Jan; 123(1):40-9. PubMed ID: 16989918
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic potentials of glycoprotein C-negative syncytial mutants from rabbit T cells infected persistently with herpes simplex virus type 1.
Ishida Y; Okabe T; Azukizawa Y; Isono T; Seto A
J Med Virol; 2005 May; 76(1):89-97. PubMed ID: 15779044
[TBL] [Abstract][Full Text] [Related]
14. Modified entry and syncytium formation by herpes simplex virus type 1 mutants selected for resistance to heparin inhibition.
Pertel PE; Spear PG
Virology; 1996 Dec; 226(1):22-33. PubMed ID: 8941319
[TBL] [Abstract][Full Text] [Related]
15. Establishment of latent herpes simplex virus type 1 infection in resistant, sensitive, and immunodeficient mouse strains.
Ellison AR; Yang L; Voytek C; Margolis TP
Virology; 2000 Mar; 268(1):17-28. PubMed ID: 10683323
[TBL] [Abstract][Full Text] [Related]
16. Implications for herpes simplex virus vaccine strategies based on antibodies produced to herpes simplex virus type 1 glycoprotein gC immune evasion domains.
Chang YJ; Jiang M; Lubinski JM; King RD; Friedman HM
Vaccine; 2005 Sep; 23(38):4658-65. PubMed ID: 15936852
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans.
Marchetti M; Trybala E; Superti F; Johansson M; Bergström T
Virology; 2004 Jan; 318(1):405-13. PubMed ID: 14972565
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
19. Basic amino acids as modulators of an O-linked glycosylation signal of the herpes simplex virus type 1 glycoprotein gC: functional roles in viral infectivity.
Mårdberg K; Nyström K; Tarp MA; Trybala E; Clausen H; Bergström T; Olofsson S
Glycobiology; 2004 Jul; 14(7):571-81. PubMed ID: 15044392
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein D homologs in herpes simplex virus type 1, pseudorabies virus, and bovine herpes virus type 1 bind directly to human HveC(nectin-1) with different affinities.
Connolly SA; Whitbeck JJ; Rux AH; Krummenacher C; van Drunen Littel-van den Hurk S; Cohen GH; Eisenberg RJ
Virology; 2001 Feb; 280(1):7-18. PubMed ID: 11162814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
